MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...

8 old programming languages developers won’t quit Newer languages might soak up all the glory, but these die-hard languages have their place. Here are eight languages developers still use daily, and ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...